서울대학교 중앙도서관
S-Space 소개
My S-Space
로그인이 필요합니다.
Login

S-Space

Browse

Subject

Jump to a point in the index
Or type in a year

  • Sort by
  • In order
  • Results/Page
  • Authors/record

Showing results 1 to 12 of 12

Issue DateTitle / Author(s) / CitationFileAltmetrics
2010-12
Rapid and Dramatic Radiographic and Clinical Response to an ALK Inhibitor (Crizotinib, PF02341066) in an ALK Translocation-Positive Patient with Non-small Cell Lung Cancer
DOI
2011-03
Screening of anaplastic lymphoma kinase rearrangement by immunohistochemistry in non-small cell lung cancer: Correlation with fluorescence in situ hybridization
DOI
2012-06
Remarkable Tumor Response to Crizotinib in a 14-Year-Old Girl With ALK-Positive Non-Small-Cell Lung Cancer

Kim, Su-Jung; Kim, Dong-Wan; Kim, Tae Min; Lee, Se-Hoon; Heo, Dae Seog; Bang, Yung-Jue

Journal of Clinical Oncology, Vol.30 No.16, pp.E147-E150

DOI
2012-08
Heterogeneity of genetic changes associated with acquired crizotinib resistance in Anaplastic lymphoma kinase-rearranged lung cancer
view file
2012-10
Treatment of ALK-Positive Non-Small Cell Lung Cancer

Bang, Yung-Jue

Archives of Pathology and Laboratory Medicine, Vol.136 No.10, pp.1201-1204

DOI
2013-01
Multiplexed Gene Expression and Fusion Transcript Analysis to Detect ALK Fusions in Lung Cancer
DOI
2013-04
Heterogeneity of Genetic Changes Associated with Acquired Crizotinib Resistance in ALK-Rearranged Lung Cancer
DOI
2013-10
A Comprehensive Comparative Analysis of the Histomorphological Features of ALK-Rearranged Lung Adenocarcinoma Based on Driver Oncogene Mutations: Frequent Expression of Epithelial-Mesenchymal Transition Markers than Other Genotype
DOI
2014-08
ALK Molecular Phenotype in Non-Small Cell Lung Cancer: CT Radiogenomic Characterization
DOI
2015-11
Targeting stemness is an effective strategy to control EML4-ALK(+) non-small cell lung cancer cells
view fileDOI
2016-08
Combined cetuximab and pemetrexed therapy enhances cytotoxicity against crizotinib resistant non-small cell lung cancer cells by downregulating thymidylate synthase
view file
2017-09
ASCEND-8: A randomized phase 1 study of ceritinib, 450 mg or 600 mg, taken with a low-fat meal versus 750 mg in fasted state in patients with anaplastic lymphoma kinase (ALK)-rearranged metastatic non-small cell lung cancer (NSCLC)
DOI
1